← Leaderboards
Robert Anthony Marr
Rosalind Franklin Univ Of Medicine & Sci
$1,518,326
Attributed
$1,732,826
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $439.3K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,732,826 · 4
By mechanism
R21$1,732,826 · 4
Top collaborators
- Grace E. Stutzmann2 shared
Most similar at Rosalind Franklin Univ Of Medicine & Sci
Same institution · by research overlap
- Grace E. Stutzmann$5,913,367
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAffectPathway InteractionsMemoryPathologyBrainAmyloid Beta-ProteinResponseAcutePeptidesDementiaS DiseaseObject RecognitionTau ProteinsLinkCerebrumLearningMorris Water MazeTransgenic MiceEffective TherapyEndopeptidasesAbeta ClearanceInjuryBehavioral
Grant awards (7)
Pharmacological inhibition of NEP-like enzymes in traumatic brain injury and dementia$197,375
R21 · FY2025 · NS · contact PI
Pharmacological inhibition of NEP-like enzymes in traumatic brain injury and dementia$236,850
R21 · FY2024 · NS · contact PI
The development of gene therapeutic approaches to suppress cerebral inflammation in dementia$429,000
R21 · FY2022 · AG · contact PI
Nep-like endopeptidases in traumatic brain injury and the associated dementias$196,297
R21 · FY2017 · NS · contact PI
Nep-like endopeptidases in traumatic brain injury and the associated dementias$244,304
R21 · FY2016 · NS · contact PI
Validating novel ryanodine receptor-targeted compounds for AD therapeutics$195,000
R21 · FY2016 · AG
Validating novel ryanodine receptor-targeted compounds for AD therapeutics$234,000
R21 · FY2015 · AG